PeppiLibrary

Healing

Pentadeca Arginate peptide reference

Arginate-stabilised analog of BPC-157. Marketed for improved stability and shelf life.

Last reviewed May 6, 2026 Research Not FDA approved
Peppi reviewing Pentadeca Arginate notes
Default dose label250 mcg
Preferred routeSubQ
Frequency label1–2× daily
Storage window60 days mixed

Evidence snapshot

Research

Evidence maturityResearch
Inferred from BPC-157 parent literature; independent PDA-specific data sparse

Research chemical / compounded variant

Route map

How records are usually labeled

1 SubQ
2 IM

Inject as close to the area being treated as practical.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C — suppliers claim 60+ days, but independent verification is limited.
Use-by cue60 days after mixing
Mixed vial window60 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 10 mg vial
Dose 250 mcg
Route SubQ
Review 60d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for Pentadeca Arginate. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

Pentadeca Arginate (PDA) is a marketing/research designation for a BPC-157 analog where the parent peptide is paired with arginine salts intended to improve stability in solution. The 15-amino-acid backbone matches BPC-157; the arginate salt form is reported by suppliers to have a longer reconstituted shelf life. Independent peer-reviewed pharmacology data is limited.

Also known as: PDA, Arginate-modified BPC.

Tendon and ligament recoveryJoint painGut barrier integrity

Mechanism and timing snapshot

Same parent peptide pharmacology as BPC-157 — angiogenic, gut-protective, and tendon-recovery effects. Arginate counterion is reported to improve stability rather than change pharmacology.

Onset label15 min
Catalog onset field, when available.
Half-life label4 hr
Assumed similar to BPC-157 (~4 hours subQ); independent PK data limited
Duration label8 hr
Catalog duration field, when available.
subQ High
oral Low

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose250 mcg
Catalog dose range200 mcg - 1 mg
Default routeSubQ
Frequency label1–2× daily
Best time labelAnytime; near injury site for localised issues.
Food noteNone.

Catalog protocol note

250 mcg subQ 1–2× daily for 4–6 weeks. Same protocol as BPC-157.

Routes and site notes

Available route labelsSubQ, IM
Preferred route labelSubQ
Common site labelsAbdomen, Near injury site
Site rotation noteInject as close to the area being treated as practical.

Chemistry

SequenceGEPPPGKPADDAGLV (BPC-15 backbone) · arginate counterion
Amino acids15
Molecular formulaC62H98N16O22 · arginine salts
Molecular weight1419.5 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size10 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note10 mg in 2 mL → 0.05 mL = 250 mcg (5 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C — suppliers claim 60+ days, but independent verification is limited.
Reconstituted shelf life60 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Mild flushing at injection site
  • Occasional fatigue
  • Headache

Contraindications and warnings

  • Active malignancy (theoretical, same as BPC-157)
  • Not FDA-approved.
  • Independent peer-reviewed studies of the arginate salt form are very limited; most claims come from suppliers.

Other considerations

  • Pharmacology is assumed to mirror BPC-157 — most published research is on the parent peptide.
  • If your BPC-157 already lasts 30 days reconstituted, the longer shelf-life claim may not justify a price premium.

Evidence and regulatory context

Evidence levelInferred from BPC-157 parent literature; independent PDA-specific data sparse
FDA approvedNo
Regulatory statusResearch chemical / compounded variant
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withtb-500
Avoid combining notebpc-157 (redundant)
Typical cycle label4–6
Typical break label2–4
Cycle guidanceSame as BPC-157. 4–6 week cycles with breaks.

Tracking tips

  • Treat protocols as identical to BPC-157 unless your supplier provides independent PK data.
  • Arginate stability claims are marketing — verify with refrigerator-test in your own use.
  • If you already use BPC-157 successfully, switching to PDA is not necessarily an upgrade.

References

Track it in Peppi

Keep Pentadeca Arginate records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for Pentadeca Arginate?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use Pentadeca Arginate?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export Pentadeca Arginate records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026